Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Pexidartinib Upfront in a Case of Tenosynovial Giant Cell Tumor: Proof of Concept for a Treatment Paradigm Shift

Oncology and Therapy(2024)10.1007/s40487-024-00298-zSource: DataRank Database

Pexidartinib Upfront in a Case of Tenosynovial Giant Cell Tumor: Proof of Concept for a Treatment Paradigm Shift is a research paper published in Oncology and Therapy (2024). On theSindex it has a DataRank of 0.283. It has been cited 5 times, with 3 citing works in its 1-hop citation network.

N/A

0.283DataRank · unranked

Scored on demand from live citation data

5 citations · 3 citing works in its network

Download PDF

Cite:

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (1 grants)Impact (FWCI 1.26)OA: goldTopics (21)IDs (PubMed, PMC, OpenAlex)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (0/2)

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

DataRank Breakdown

Base Score 95%Citation Network 5%

Base Score Contribution

0.269

From this paper's citation signal

Citation Network Contribution

0.0144

From 1 citing papers with measurable signal

Learn more about DataRank methodology →

Top 3 citers driving the network score

Ranked by each citer's contribution to N(p) — log1p(C_q) divided by its reference count — out of 3 citers.

Tenosynovial giant cell tumor (TGCT): Mechanisms and advances in targeted treatments
Critical Reviews in Oncology/Hematology20252 citations65 referencesContributes 0.017
Diffuse tenossinovial giant cell tumor: A systematic review on management and treatment strategies
Journal of Orthopaedic Reports20250 citations89 referencesContributes 0.000
Pexidartinib: Current advances in the symptomatic treatment of tenosynovial giant cell tumors
Cancer and Metastasis Reviews20260 citations87 referencesContributes 0.000

Authors (3)

Giuliano Peta,Gianmarco Tuzzato,Emanuela Palmerini ORCID

Live enrichment

PubMed:39155359 PMC:PMC11573934 OpenAlex:https://openalex.org/W4401697954

Daiichi Sankyo, Inc.

FWCI

1.26

Citation Percentile

0.8%

Citation Trend

2025

2026

goldLicense: cc-by-nc

journalhttps://doi.org/10.1007/s40487-024-00298-z

publisherhttps://doi.org/10.1007/s40487-024-00298-z

publisherhttps://link.springer.com/content/pdf/10.1007/s40487-024-00298-z.pdf

publisherhttps://link.springer.com/article/10.1007/s40487-024-00298-z/fulltext.html

repositoryhttps://pubmed.ncbi.nlm.nih.gov/39155359

Fields of Study

Musculoskeletal synovial abnormalities and treatmentsTendon Structure and TreatmentBone Tumor Diagnosis and Treatments

Keywords

Proof of conceptParadigm shiftBurden of proofComputer scienceMedicineEpistemologyPhilosophyPolitical scienceLawSafetySurgeryefficacyCase ReportSystemic TherapyCsf-1TgctTenosynovial Giant Cell TumorPexidartinib

Sustainable Development Goals

SDG 0: Good health and well-being